Nivolumab,Relatlimab
bms
['melanoma']
safety data are what we ve seen previously with this combo. #melanoma #asco22 
Melanoma+Cell Therapy Oncologist @MSKCancerCenter| Cornell/DukeMed/ MGH IM/MSKCC Onc alum | FCOI: https://t.co/kwtet64Pe4